dr. jonasch on the safety profile of mk-6482 in von hippel-lindau disease–associated rcc
Published 4 years ago • 70 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
1:48
dr. jonasch on next steps with mk-6482 in von hippel-lindau disease–associated rcc
-
2:15
mk-6482 shows promise in von hippel-lindau disease-associated renal cell carcinoma
-
1:00
eric jonasch, md, discusses the incidence of von hippel-lindau disease among rcc patients
-
3:28
mk-6482 to treat renal cell carcinoma in von hippel-lindau disease patients
-
1:52
eric jonasch, md, explains the development process for mk-6482 and hopes for future studies
-
2:21
phase ii study of the oral hif-2α inhibitor mk-6482
-
5:29
a webinar sneak peek: von hippel-lindau disease treatment advances with eric jonasch, md
-
1:10
dr. jonasch on molecular understanding of clear cell rcc
-
1:04
dr. jonasch on modulating the tumor microenvironment in rcc
-
1:04
dr. jonasch on first- and second-line options for patients with rcc
-
0:53
dr. jonasch on the potential of immunotherapy for sarcomatoid rcc
-
0:54
dr. jonasch on promise of immuno-oncology agents in rcc
-
1:14
dr. jonasch on single-agent pembrolizumab in non-clear cell rcc
-
4:53
data from von-hippel-lindau clinical trial shows promise for hif-2a inhibitor
-
2:48
oral hif-2 α inhibitor mk-6482 in patients with advanced clear cell renal cell carcinoma
-
6:22
von hippel lindau disease - case based discussion usmle step 1 pathology
-
0:34
myvhl and dr. eric jonasch - the vhl alliance
-
1:38
#kcrs19: eric jonasch, m.d.
-
2:36
papillary cystadenoma of the epididymis - von hippel lindau #radiology #vhl #urology